Evaluation of six CTLA-4 polymorphisms in high-risk melanoma patients receiving adjuvant interferon therapy in the He13A/98 multicenter trial

PURPOSE: Interferon is approved for adjuvant treatment of patients with stage IIb/III melanoma. The toxicity and uncertainty regarding survival benefits of interferon have qualified its acceptance, despite significant durable relapse prevention in a fraction of patients. Predictive biomarkers that w...

Descripción completa

Detalles Bibliográficos
Autores principales: Gogas, Helen, Dafni, Urania, Koon, Henry, Spyropoulou-Vlachou, Maria, Metaxas, Yannis, Buchbinder, Elizabeth, Pectasides, Eirini, Tsoutsos, Dimosthenis, Polyzos, Aristidis, Stratigos, Alexandros, Markopoulos, Christos, Panagiotou, Petros, Fountzilas, George, Castana, Ourania, Skarlos, Pantelis, Atkins, Michael B, Kirkwood, John M
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2010
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2988721/
https://www.ncbi.nlm.nih.gov/pubmed/21044351
http://dx.doi.org/10.1186/1479-5876-8-108

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2988721/
https://www.ncbi.nlm.nih.gov/pubmed/21044351
http://dx.doi.org/10.1186/1479-5876-8-108

Ejemplares similares